PAVmed Inc. (PAVM) Fair Value 2026

PAVM · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 6 models active

Value Trap Risk

WARN (58/100)

Quick Summary — As of 2026-08-28, PAVmed Inc. (PAVM) trades at $4.92, versus a $1.39 median fair value across its 6 active models — 71.7% below the current price. QOC: 4.6/10. Value Trap Risk: 58/100 (WARN). 6/13 models active. Within that set, the Bayesian DCF component alone returns $0.24.

Key Facts

Ticker
PAVM
Price
$4.92
Quality Score
4.6/10
Value Trap Risk
58/100
Models Active
6/13
Last Updated
Strength: 6 independent models provide multi-angle coverage
Risk: Value Trap score of 58 suggests caution despite apparent undervaluation

Is PAVmed Inc. (PAVM) Undervalued or Overvalued in 2026?

According to CirclFi’s 6-model valuation engine, PAVmed Inc. (PAVM) appears overvalued as of : the median of 6 independent fair value estimates is $1.39, 71.7% below the current price of $4.92. Estimates range from $0.24 to $5.30. PAVM scores 4.6/10 on fundamental quality and 58/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. PAVM’s -71.7% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy PAVmed Inc. Stock in 2026? →

What Fair Value Does Each Model Give PAVM?

6 Intrinsic Value Models vs. Current Price ($4.92)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $0.24 -95.2%
Ensemble · Low Conviction
 $1.70 -65.5%
Asset-Based · Medium Conviction
 $4.48 -8.9%
Unlock the Full Matrix

Access 3 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 6 Models →

Cancel anytime · No contracts · Instant access

What Is PAVM's Fair Value Range?

Spread across 6 independent models · $0.24 to $5.30

CirclFi's 6 active models place PAVmed Inc. (PAVM) between $0.24 and $5.30 per share, a spread of 364% of the median. The median of that range — $1.39 — is the fair value CirclFi publishes for PAVM, against a current price of $4.92.

Low · Bayesian DCFHigh · PWERM
$0.24median $1.39$5.30
Where the range comes from
Most bearish modelBayesian DCF$0.24
Most bullish modelPWERM$5.30
Model agreement1 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for PAVM. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on PAVM, not a CirclFi price target. How each model works →

What Is PAVmed Inc. (PAVM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, PAVmed Inc.'s intrinsic value is estimated at $1.39. Trading at its current price of $4.92, the valuation engine raises significant caution: 5 of 6 models flag downside risk, projecting a median implied return of -71.7%. Model dispersion is worth noting: PWERM targets $5.30 (+7.7%), versus Bayesian DCF at $0.24 (-95.2%). This +102.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About PAVM?

6 of 13 models are currently active for PAVM. Of these, 1 model suggests upside while 5 models suggest overvaluation. Taken together, their median fair value for PAVM is $1.39 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.24 on its own, implying -95.2% downside from the current price. See which stocks rank higher →

How Does PAVM Rank in Medical Devices?

Among 159 Medical Devices stocks, PAVM ranks #134 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

PAVmed Inc.'s positioning within the Medical Devices segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is PAVM a Value Trap?

CirclFi's Value Trap algorithm assigns PAVM a score of 58/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

6 of 13 models are active for PAVmed Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, PAVmed Inc. earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +102.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PAVM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PAVM's 6 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy PAVmed Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

RMSLREMSleep Holdings, Inc.QOC 4.6RBOTVicarious Surgical Inc.QOC 4.6AEMDAethlon Medical, Inc.QOC 4.7CSDXCS Diagnostics Corp.QOC 4.5ALURAllurion Technologies Inc.QOC 4.8POASPhaos Technology Holdings (CaymQOC 4.5TCMDTactile Systems Technology, Inc.QOC 8.8CTKBCytek Biosciences, Inc.QOC 6.9BTCYBiotricity, Inc.QOC 6.0IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: RMSL · RBOT · AEMD · CSDX · ALUR · POAS · TCMD · CTKB · BTCY · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to PAVM?

7 companies across all industries closest to PAVM’s Quality of Company score of 4.6/10.

VERAVera Therapeutics, Inc.QOC 4.6SIONSionna Therapeutics, Inc.QOC 4.6CPHIChina Pharma Holdings, Inc.QOC 4.6EVFEaton Vance Senior Income TrustQOC 4.6LTRNLantern Pharma Inc.QOC 4.6BLNCBalance Labs, Inc.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VERA · SION · CPHI · EVF · LTRN · BLNC · NVDA

Where Does PAVM Sit in CirclFi's Medical Devices Rankings?

PAVM is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About PAVmed Inc.’s Valuation?

What is PAVmed Inc.'s intrinsic value in 2026?

CirclFi puts PAVmed Inc. (PAVM)'s intrinsic value at $1.39 — the median of 6 independent model estimates as of 2026-08-28, ranging from $0.24 to $5.30. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.24 on its own. The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PAVM overvalued or undervalued right now?

At $4.92, 1 of 6 active models suggest PAVM may be undervalued, while 5 indicate potential overvaluation. The median of all 6 fair value estimates is $1.39, 71.7% below the current price of $4.92 — a consensus view that PAVM is overvalued. The assessment depends on which methodology best fits PAVmed Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.6 mean for PAVM?

PAVmed Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PAVM?

CirclFi analyzes PAVM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 6 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on PAVM?

Of the 6 models currently active on PAVM, PWERM is the most bullish at $5.30 per share, and Bayesian DCF is the most bearish at $0.24. CirclFi's published fair value for PAVM is the median of that range, $1.39, not either extreme. The gap between the two ends equals 364% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is PAVM a value trap in 2026?

PAVmed Inc.'s Value Trap score is 58/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries.

Cite this analysis — “According to CirclFi’s 6-model valuation engine, PAVmed Inc. (PAVM) has a median fair value of $1.39 — 71.7% below the current price of $4.92 — as of 2026-08-28.” Source: circlfi.com/stock/PAVM/ · Methodology
Primary sources for this PAVM valuation
  • Financial statements: PAVmed Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001624326) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PAVM as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 6 mathematical frameworks give you clarity on PAVM.

Unlock All 6 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for PAVM Unlock All 6 — $39/mo